Klaria Pharma Licenses SAF to CNX Therapeutics for European Markets
What happened
Klaria Pharma announced that it published an external valuation of its product, Sumatriptan Alginate Film (SAF), carried out by L.E.K. Consulting. The valuation estimated potential peak sales for the migraine product at approximately USD 500 million. Klaria Pharma has licensed SAF to CNX Therapeutics for leading European markets, where CNX Therapeutics is preparing for a near-future launch.
From finanznachrichten.de
Why it matters
The agreement entitles Klaria Pharma to receive milestone payments and royalties based on sales in the covered European countries. Both revenue streams are expected to generate significant income for Klaria Pharma over the next twelve months.
From finanznachrichten.de
Who's involved
- SAFThe subject of the licensing agreement, Sumatriptan Alginate Film (SAF)
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- SudanSpeculative
The market preparation activities might affect the demand for the product in the European market.